Results 221 to 230 of about 87,967 (330)

Various subtypes of phosphodiesterase inhibitors differentially regulate pulmonary vein and sinoatrial node electrical activities. [PDF]

Exp Ther Med, 2020
Lin YK, Cheng CC, Huang JH, Chen YA, Lu YY, Chen YC, Chen SA, Chen YJ.   +7 more
europepmc   +1 more source

Phosphodiesterase 3 inhibitors boost bone outgrowth

British Journal of Pharmacology, EarlyView.
Background and Purpose C‐type natriuretic peptide (CNP) stimulates skeletal growth by acting on the growth plates of long bones, and a CNP variant is clinically used for achondroplasia treatment. We previously reported that CNP stimulates the autonomic Ca2+ influx mediated by TRPM7 channels in growth plate chondrocytes to facilitate extracellular ...
Takaaki Kawabe, Atsuhiko Ichimura, Tomoki Yasue, Jianhong Li, Haruki Ishikawa, Ga Eun Kim, Hiroki Nagatomo, Naoto Minamino, Yohei Ueda, Hiromu Ito, Miyuki Nishi, Hiroshi Takeshima   +11 more
wiley   +1 more source

Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19). [PDF]

Cureus, 2020
Solaimanzadeh I.
europepmc   +1 more source

A developmentally regulated and cAMP-repressible gene of Dictyostelium discoideum: cloning and expression of the gene encoding cyclic nucleotide phosphodiesterase inhibitor

, 1990
Lin Wu, Jakob Franke
openalex   +1 more source

The Application of Polymeric Nanoparticles as Drug Delivery Carriers to Cells in Neurodegenerative Diseases

Cell Proliferation, EarlyView.
Polymeric nanoparticles represent promising drug (gene) delivery carriers to the brain due to their unique advantages to facilitate the penetration of blood–brain barrier and endocytosis of neuronal cells in neurodegenerative diseases. ABSTRACT In spite of great advances in modern medicine, there are a few effective strategies for the treatment of ...
Lian Jin, Libo Nie, Yan Deng, Ghulam Jilany Khana, Nongyue He   +4 more
wiley   +1 more source

Substituted 1,8-Naphthyridin-2(1H)-ones as Selective Phosphodiesterase IV Inhibitors.

, 1994
Akihiro Matsuura, Naoki Ashizawa, Reiji Asakura, T Kumonaka, T Aotsuka, Tadashi Hase, Chikako Shimizu, T. KURIHARA, F. Kobayashi   +8 more
openalex   +2 more sources

Modulation of spasmogen‐stimulated Ins(1,4,5)P₃ generation and functional responses by selective inhibitors of types 3 and 4 phosphodiesterase in airways smooth muscle [PDF]

, 1998
R. A. John Challiss, David Adams, Rajendra Mistry, C. D. Nicholson   +3 more
openalex   +1 more source

A phase IIb single‐center study to assess the efficacy of apremilast for the treatment of nummular eczema

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background The pathogenesis of nummular eczema (NE) remains unclear, and no targeted therapy has been approved. Apremilast is a small molecule inhibitor targeting phosphodiesterase‐4. Patients and Methods A phase IIb randomized, double‐blind, placebo‐controlled study evaluating the effects of apremilast or placebo in patients with NE.
Alexander Böhner, Peter Seiringer, Viktoria Kleeberger, Danielle Rogner, Christian Oesterlin, Tilo Biedermann, Kilian Eyerich, Felix Lauffer   +7 more
wiley   +1 more source

Inhibitory effect of a novel selective and potent phosphodiesterase type V inhibitor, E4021, on ST segment elevation induced by vasopressin in anesthetized guinea pigs.

, 1994
Kohtarou Kodama, Hideyuki Adachi, Nobuyuki Mori   +2 more
openalex   +1 more source

First‐line diagnostic tests to intercept primary heart involvement in systemic sclerosis: Clinical associations from the SPRING‐SIR registry

European Journal of Clinical Investigation, EarlyView.
Primary heart involvement (pHI) is a severe but often overlooked complication of systemic sclerosis (SSc), linked to heart failure, arrhythmias and mortality. In a study of 600 patients from the Italian SPRING‐SIR registry, 25% had ECG or echocardiographic signs of pHI at baseline, associated with older age, diffuse skin disease and intestinal symptoms.
Antonio Tonutti, Francesca Motta, Rossella De Angelis, Edoardo Cipolletta, Clodoveo Ferri, Gianluigi Bajocchi, Silvia Bellando‐Randone, Cosimo Bruni, Martina Orlandi, Giovanni Zanframundo, Rosario Foti, Giovanna Cuomo, Alarico Ariani, Edoardo Rosato, Gemma Lepri, Francesco Girelli, Elisabetta Zanatta, Silvia Laura Bosello, Ilaria Cavazzana, Francesca Ingegnoli, Fabio Cacciapaglia, Giuseppe Murdaca, Giuseppina Abignano, Giorgio Pettiti, Alessandra Della Rossa, Maurizio Caminiti, Anna Maria Iuliano, Giovanni Ciano, Lorenzo Beretta, Gianluca Bagnato, Ennio Lubrano, Ilenia De Andres, Luca Idolazzi, Marta Saracco, Cecilia Agnes, Corrado Campochiaro, Marco Fornaro, Federica Lumetti, Amelia Spinella, Luca Magnani, Giacomo De Luca, Veronica Codullo, Elisa Visalli, Carlo Iandoli, Antonietta Gigante, Greta Pellegrino, Erika Pigatto, Maria Grazia Lazzaroni, Enrico De Lorenzis, Gianna Mennillo, Marco Di Battista, Giuseppa Pagano‐Mariano, Federica Furini, Licia Vultaggio, Simone Parisi, Clara Lisa Peroni, Gerolamo Bianchi, Enrico Fusaro, Gian Domenico Sebastiani, Marcello Govoni, Salvatore D'Angelo, Franco Cozzi, Franco Franceschini, Serena Guiducci, Lorenzo Dagna, Andrea Doria, Dilia Giuggioli, Valeria Riccieri, Carlo Salvarani, Florenzo Iannone, Marco Matucci‐Cerinic, Carlo Selmi, Maria De Santis, on behalf of SPRING‐SIR (Systemic Sclerosis PRogression INvestiGation group of the Italian Society for Rheumatology), Giorgio Amato, Alessia Benenati, Francesca Calabrese, Renato Carignola, Francesca Dall’Ara, Angelo De Cata, Claudio Di Vico, Marica Doveri, Nicoletta Romeo, Elena Generali, Gianluca Sambataro, Rossella Talotta, Alberto Lo Gullo, Carlo Scirè, Greta Carrara, Giampiero Landolfi, Davide Rozza, Anna Zanetti   +91 more
wiley   +1 more source